New Strong Sell Stocks for July 28th
LUNR, GLDG and BCDA have been added to the Zacks Rank #5 (Strong Sell) List on July 28, 2026.
Zacks Investment Research7/28/2026Negative
BCDA
Biocardia IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$12.03M
P/E Ratio
—
EPS
$-0.81
Beta
0.44
52W High
$2.29
52W Low
$0.75
50-Day MA
$0.95
200-Day MA
$1.19
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About Biocardia Inc
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapies for cardiovascular disease. The company is headquartered in San Carlos, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-4.67M |
| EBITDA | $-7.80M |
| Operating Margin | 0.00% |
| Return on Equity | -950.00% |
| Return on Assets | -252.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.10 |
| Price-to-Book | 12.35 |
| Price-to-Sales (TTM) | 2520.59 |
| EV/Revenue | 23.81 |
| EV/EBITDA | -3.16 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $14.88M |
| Float | $8.52M |
| % Insiders | 23.50% |
| % Institutions | 5.46% |
Historical Volatility
HV 10-Day
85.58%
HV 20-Day
93.00%
HV 30-Day
94.05%
HV 60-Day
88.08%
HV Rank
80.2%
Volatility is currently contracting
Analyst Ratings
Consensus ($15.50 target)
2
BuyLatest News
New Strong Sell Stocks for July 14th
AZ, AISP and BCDA have been added to the Zacks Rank #5 (Strong Sell) List on July 14th, 2026.
Zacks Investment Research7/14/2026Negative
BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities
SUNNYVALE, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the Company's Chief Executive Officer, Peter Altman, issued the following letter to shareholders.
GlobeNewsWire6/18/2026Neutral
FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF
SUNNYVALE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced receipt of FDA minutes from its Q-Sub Meeting with FDA Center for Biologics Evaluation and Research (CBER) on the CardiAMP Cell Therapy System for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF).
GlobeNewsWire6/5/2026Neutral
BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency
– Positive CardiAMP CMI Trial open-label cohort results demonstrated opportunity for locally delivered cell therapy to enhance therapeutic options for patients with severely symptomatic refractory angina and validate continued clinical development – Novel therapeutic approach targets a critically important unmet medical need for patients who have debilitated quality-of-life and have exhausted all available treatment options SUNNYVALE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the oral presentation of the results of the CardiAMP® Cell Therapy in Chronic Myocardial Ischemia Trial (CardiAMP CMI) preliminary open label cohort at EuroPCR, a leading interventional cardiovascular medicine conference held in Paris.
GlobeNewsWire5/21/2026Neutral
BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript
BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript
Seeking Alpha5/15/2026Neutral
BioCardia Reports First Quarter 2026 Business Highlights and Financial Results
SUNNYVALE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter 2026 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2026 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session.
GlobeNewsWire5/15/2026Neutral
BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure
SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported a positive outcome in its formal clinical consultation with Japan's Pharmaceutical and Medical Device Agency (PMDA). PMDA has determined that the clinical safety and efficacy evidence for the CardiAMP® Cell Therapy in ischemic heart failure is likely sufficient to support market clearance.
GlobeNewsWire4/20/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BCDA and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 7/29/2026